Beta Nerve Growth Factor (Beta NGF or NGF) Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update
Powered by
All the vital news, analysis, and commentary curated by our industry experts.
The nerve growth factor is a neurotrophic factor involved in the regulation of growth, maintenance, proliferation, and survival of certain target neurons. It inhibits metalloproteinase-dependent proteolysis of platelet glycoprotein VI.
The beta nerve growth factor drugs in development market report provides an in-depth analysis of Beta NGF or NGF targeted pipeline therapeutics. The report provides comprehensive information on the Beta Nerve Growth Factor targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA), and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history, and the latest news and press releases. Additionally, the report provides an overview of key players involved in Beta NGF targeted therapeutics development with respective active and dormant or discontinued projects.
What are the mechanisms of action of the Beta NGF pipeline drugs market?
The mechanisms of action of the Beta NGF pipeline drugs market are Beta Nerve Growth Factor Inhibitor, Beta Nerve Growth Factor Activator, Tumor Necrosis Factor Inhibitor, and Brain Derived Neurotrophic Factor Activator.
Beta NGF pipeline drugs market, by mechanisms of action
For more mechanisms of action insights, download a free report sample
What are the routes of administration in the Beta NGF pipeline drugs market?
The routes of administration in the Beta NGF pipeline drugs market are subcutaneous, intravenous, ophthalmic, parenteral, and intramuscular.
Beta NGF pipeline drugs market, by routes of administration
For more routes of administration insights, download a free report sample
What are the molecule types in the Beta NGF pipeline drugs market?
The molecule types in the Beta NGF pipeline drugs market are monoclonal antibody, small molecule, aptamer, gene therapy, and recombinant protein.
Beta NGF pipeline drugs market, by molecule types
For more molecule type insights, download a free report sample
Which are the key companies in the Beta NGF pipeline drugs market?
Some of the key companies in the Beta NGF pipeline drugs market are Akeso Inc, AstraZeneca Plc, Chengdu Easton Biopharmaceuticals Co Ltd, Dartsbio Pharmaceutical (Guangdong) Co Ltd, Fujimoto Pharmaceutical Corp, MimeTech Srl, Regeneron Pharmaceuticals Inc, Shandong Boan Biotechnology Co Ltd, Staidson BioPharma Inc, and Zhuhai Trinomab Biotechnology Co Ltd.
Beta NGF pipeline drugs market, by key companies
To know more about key companies, download a free report sample
Market report scope
Mechanisms of Action | Beta Nerve Growth Factor Inhibitor, Beta Nerve Growth Factor Activator, Tumor Necrosis Factor Inhibitor, and Brain Derived Neurotrophic Factor Activator |
Routes of Administration | Subcutaneous, Intravenous, Ophthalmic, Parenteral, and Intramuscular |
Molecule Types | Monoclonal Antibody, Small Molecule, Aptamer, Gene Therapy, and Recombinant Protein |
Key Companies | Akeso Inc, AstraZeneca Plc, Chengdu Easton Biopharmaceuticals Co Ltd, Dartsbio Pharmaceutical (Guangdong) Co Ltd, Fujimoto Pharmaceutical Corp, MimeTech Srl, Regeneron Pharmaceuticals Inc, Shandong Boan Biotechnology Co Ltd, Staidson BioPharma Inc, and Zhuhai Trinomab Biotechnology Co Ltd |
This report provides:
- A snapshot of the global therapeutic landscape of Beta Nerve Growth Factor (Beta NGF or NGF).
- Reviews of pipeline therapeutics for Beta Nerve Growth Factor (Beta NGF or NGF) by companies and universities/research institutes based on information derived from company and industry-specific sources.
- Pipeline products based on several stages of development ranging from pre-registration to discovery and undisclosed stages.
- Descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
- Key companies involved in Beta Nerve Growth Factor (Beta NGF or NGF) therapeutics and enlists all their major and minor projects.
- Evaluation of Beta Nerve Growth Factor (Beta NGF or NGF) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA), and molecule type.
- All the dormant and discontinued pipeline projects.
- Reviews of the latest news related to pipeline therapeutics for Beta Nerve Growth Factor (Beta NGF or NGF).
Reasons to Buy
- Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
- Recognize emerging players with potentially strong product portfolio and create effective counterstrategies to gain competitive advantage.
- Find and recognize significant and varied types of therapeutics under development for Beta Nerve Growth Factor (Beta NGF or NGF).
- Classify potential new clients or partners in the target demographic.
- Develop tactical initiatives by understanding the focus areas of leading companies.
- Plan mergers and acquisitions meritoriously by identifying key players and their most promising pipeline therapeutics.
- Formulate corrective measures for pipeline projects by understanding Beta Nerve Growth Factor (Beta NGF or NGF) pipeline depth and focus of Indication therapeutics.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
- Adjust the therapeutic portfolio by recognizing discontinued projects and understanding from the know-how what drove them from the pipeline.
AstraZeneca Plc
Chengdu Easton Biopharmaceuticals Co Ltd
Dartsbio Pharmaceutical (Guangdong) Co Ltd
Fujimoto Pharmaceutical Corp
MimeTech Srl
Regeneron Pharmaceuticals Inc
Shandong Boan Biotechnology Co Ltd
Staidson BioPharma Inc
Zhuhai Trinomab Biotechnology Co Ltd
Table of Contents
Table
Figures
Frequently asked questions
-
What are the mechanisms of action of the Beta NGF pipeline drugs market?
The mechanisms of action of the Beta NGF pipeline drugs market are Beta Nerve Growth Factor Inhibitor, Beta Nerve Growth Factor Activator, Tumor Necrosis Factor Inhibitor, and Brain Derived Neurotrophic Factor Activator.
-
What are the routes of administration in the Beta NGF pipeline drugs market?
The routes of administration in the Beta NGF pipeline drugs market are subcutaneous, intravenous, ophthalmic, parenteral, and intramuscular.
-
What are the molecule types in the Beta NGF pipeline drugs market?
The molecule types in the Beta NGF pipeline drugs market are monoclonal antibody, small molecule, aptamer, gene therapy, and recombinant protein.
-
Which are the key companies in the Beta NGF pipeline drugs market?
Some of the key companies in the Beta NGF pipeline drugs market are Akeso Inc, AstraZeneca Plc, Chengdu Easton Biopharmaceuticals Co Ltd, Dartsbio Pharmaceutical (Guangdong) Co Ltd, Fujimoto Pharmaceutical Corp, MimeTech Srl, Regeneron Pharmaceuticals Inc, Shandong Boan Biotechnology Co Ltd, Staidson BioPharma Inc, and Zhuhai Trinomab Biotechnology Co Ltd.
Get in touch to find out about multi-purchase discounts
reportstore@globaldata.com
Tel +44 20 7947 2745
Every customer’s requirement is unique. With over 220,000 construction projects tracked, we can create a tailored dataset for you based on the types of projects you are looking for. Please get in touch with your specific requirements and we can send you a quote.